Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects

Drug Metabolism and Disposition

Volumn 41, Issue 9, 2013, Pages 1626-1641

  Walles, Markus ^a   Wolf, Thierry ^a   Jin, Yi ^a   Ritzau, Michael ^a   Leuthold, Luc Alexis ^a   Krauser, Joel ^a   Gschwind, Hans Peter ^a   Carcache, David ^a   Kittelmann, Matthias ^a   Ocwieja, Magdalena ^a   Ufer, Mike ^a   Woessner, Ralph ^a   Chakraborty, Abhijit ^a   Swart, Piet ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID; BENZYL ALCOHOL; CARBON 14; CYTOCHROME P450; DRUG METABOLITE; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER;

AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT;

ABSORPTION; ADULT; AREA UNDER CURVE; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; FECES; HALF-LIFE; HUMANS; INDOLES; MALE; MICROSOMES, LIVER; OXIDATION-REDUCTION; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84882773330     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050716     Document Type: Article

References (18)

1. Ahlskog JE and Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
2. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, and Ries V, et al. (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26:1243-1250.
3. Chase TN and Oh JD (2000) Striatal dopamine-And glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23(10, Suppl):S86-S91.
4. Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, and Di Paolo T (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-Treated parkinsonian monkeys. Parkinsonism Relat Disord 17:270-276.
5. Hauser RA (2009) Levodopa: past, present, and future. Eur Neurol 62:1-8.
6. Hinderling PH (1997) Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 49:279-295.
7. International Commission on Radiological Protection (ICRP) (1991) 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Ann ICRP 21: 1-201.
8. Ioannides C and Parke DV (1990) The cytochrome P450 I gene family of microsomal hemoproteins and their role in the metabolic activation of chemicals. Drug Metab Rev 22: 1-85.
9. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, and Paulding C, et al. (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3:64ra1 DOI: 0.1126/scitranslmed.3001708.
10. Krauser J, Walles M, Wolf T, Graf D, and Swart P (2012) A unique automation platform for measuring low level radioactivity in metabolite identification studies. PLoS ONE 7:e39070.
11. Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, Song C, Buijsen RA, Pop AS, and Gomezmancilla B, et al. (2011) AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42:311-317.
12. Mela F, Marti M, Dekundy A, Danysz W, Morari M, and Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 101:483-497.
13. Morin N, Grégoire L, Gomez-Mancilla B, Gasparini F, and Di Paolo T (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58:981-986.
14. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
15. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, and Cenci MA (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330:227-235.
16. Tang L and Kebarle P (1993) Dependence of ion intensity in electrospray mass spectrometry on the concentration of the analytes in the electrosprayed solution. Anal Chem 65:3654-3668 DOI:10.1021/ac00072a020.
17. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, and El-Kattan A (2009) Physicochemical determinants of human renal clearance. J Med Chem 52:4844-4852.
18. Yumibe N, Huie K, Chen KJ, Snow M, Clement RP, and Cayen MN (1996) Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 51:165-172.